Pharmacology · Sedative-Hypnotic Drugs

Benzodiazepines

GABA-A receptor pharmacology, clinical indications, and key distinctions

Benzodiazepines are positive allosteric modulators of the GABA-A receptor — they bind the alpha-gamma subunit interface and increase the frequency of chloride channel opening in the presence of GABA, requiring GABA to be present (unlike barbiturates, which can directly activate the channel).
Duration of action spans from ultra-short (triazolam) to long-acting (diazepam) based on half-life and active metabolite generation; the LOT agents (lorazepam, oxazepam, temazepam) undergo only glucuronidation with no active metabolites, making them predictable in the elderly and in hepatic impairment.
Acute seizure indications vary by route: IV lorazepam is the hospital standard for status epilepticus; IM midazolam is preferred when IV access is unavailable (RAMPART trial showed non-inferiority); diazepam and chlordiazepoxide are preferred for alcohol withdrawal due to their self-tapering long half-lives.
Flumazenil is a competitive GABA-A antagonist with a 40–80 minute half-life — shorter than all benzodiazepines it reverses; it is absolutely contraindicated in physically dependent patients (precipitates refractory seizures) and when TCA co-ingestion is suspected.
The opioid-benzodiazepine combination carries a boxed warning — it produces synergistic respiratory depression greater than either agent alone and is a leading cause of drug overdose deaths; overdose management must address both drug classes.

Mechanism of Action

Target

GABA-A receptor — ligand-gated chloride channel. Benzodiazepines bind the alpha-gamma subunit interface (allosteric site, distinct from the GABA binding site).

Effect

Positive allosteric modulator: increases frequency of chloride channel opening in the presence of GABA. Does not directly open the channel. Requires GABA to be present.

vs. Barbiturates

Barbiturates increase duration of opening and can directly activate at high doses — no GABA required. No ceiling effect. Higher lethality in overdose. Benzodiazepines have a ceiling on receptor activation: safer in isolated overdose.

Pharmacokinetic Spectrum

Category	Agents	Key Feature	Primary Use
Ultra-short	Triazolam	Half-life 1.5–5 hours. Rebound insomnia, amnesia.	Rarely used now
Short (LOT)	Lorazepam, Oxazepam, Temazepam	Glucuronidation only. No active metabolites. Predictable offset.	Elderly, hepatic impairment, alcohol withdrawal (when accumulation is a risk)
Intermediate	Alprazolam, Clonazepam	Alprazolam: high potency, high dependence risk. Clonazepam: long half-life, once daily dosing feasible.	Panic disorder, seizure syndromes
Long-acting	Diazepam, Chlordiazepoxide	Active metabolites extend duration days to weeks. Self-tapering effect.	Alcohol withdrawal (preferred), benzodiazepine taper

Clinical Indications

Indication

Anxiety Disorders

Not first-line for chronic anxiety (SSRIs/SNRIs preferred)
Used adjunctively during antidepressant onset latency (2–4 weeks)
Alprazolam and clonazepam approved for panic disorder
Clonazepam preferred: longer half-life reduces inter-dose rebound

Indication

Acute Seizures and Status Epilepticus

First-line agents for seizure termination
IV lorazepam: standard hospital treatment (0.1 mg/kg)
IM midazolam: non-inferior to IV lorazepam in prehospital setting (RAMPART trial); preferred when IV access unavailable
Always follow with a longer-acting antiseizure agent

Indication

Alcohol Withdrawal

Agents of choice for alcohol withdrawal syndrome
Diazepam or chlordiazepoxide preferred: self-tapering long half-life
LOT agents if hepatic impairment or elderly (accumulation risk)
Dose by symptom-triggered CIWA-Ar scale

Indication

Procedural Sedation

Midazolam is the agent of choice
Short half-life (1.5–2.5 hours), rapid IV onset, reliable amnesia
Water-soluble: no venous irritation (unlike diazepam in propylene glycol)
Active metabolite accumulates in renal failure — prolonged sedation in ICU infusions

Indication

Insomnia

Reduce sleep-onset latency and increase total sleep time
Suppress slow-wave sleep and REM sleep — less restorative architecture
Rebound insomnia on discontinuation (often worse than baseline)
CBT-I is first-line; pharmacotherapy short-term only
Temazepam (LOT agent) most commonly used benzodiazepine for sleep

Flumazenil — Reversal Agent

Mechanism

Competitive antagonist at the benzodiazepine binding site. No intrinsic agonist activity. Reverses benzodiazepine sedation and respiratory depression. Half-life 40–80 minutes — shorter than all benzodiazepines it reverses.

Indication

Use Cases

Reversal of procedural sedation
Selected benzodiazepine overdose (isolated, known)
Resedation expected: monitor 1–2 hours after last dose

Contraindication

Dependent Patients

Precipitates acute withdrawal and seizures in physically dependent patients
Seizures may be refractory: flumazenil blocks the site needed to treat them
Chronic use or benzodiazepine-controlled seizures: absolute contraindication

Contraindication

TCA Co-ingestion

If benzodiazepines were used to control TCA-induced seizures, flumazenil unmasks the seizure risk
Resulting seizures cannot be treated with benzodiazepines
Suspected TCA co-ingestion: do not give flumazenil

Key Clinical Warnings

Opioid + Benzodiazepine Combination

Concurrent use produces synergistic respiratory depression greater than either agent alone. This combination carries a boxed warning and is a leading cause of drug overdose deaths. Overdose management must address both drug classes simultaneously: naloxone for opioid component, supportive care (not flumazenil routinely) for benzodiazepine component.

Suggested References

Author / Organization	Title	Source
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed. Chapter 22: Sedative-Hypnotic Drugs	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed. Chapter 17: Hypnotics and Sedatives	McGraw-Hill, 2023
Sternbach LH	The benzodiazepine story	J Med Chem. 1979;22(1):1–7
Ashton H	The diagnosis and management of benzodiazepine dependence	Curr Opin Psychiatry. 2005;18(3):249–255
Sieghart W	Structure, pharmacology, and function of GABA-A receptor subtypes	Adv Pharmacol. 2006;54:231–263
Rudolph U, Mohler H	GABA-based therapeutic approaches: GABA-A receptor subtype functions	Curr Opin Pharmacol. 2006;6(1):18–23
Greenblatt DJ, Shader RI, Abernethy DR	Current status of benzodiazepines (first of two parts)	N Engl J Med. 1983;309(6):354–358
Riss J, Cloyd J, Gates J, Collins S	Benzodiazepines in epilepsy: pharmacology and pharmacokinetics	Acta Neurol Scand. 2008;118(2):69–86
Sateia MJ, Buysse DJ, Krystal AD, et al	Clinical practice guideline for the pharmacological treatment of chronic insomnia in adults	J Clin Sleep Med. 2017;13(2):307–349
Silbergleit R, Durkalski V, Lowenstein D, et al	Intramuscular versus intravenous therapy for prehospital status epilepticus (RAMPART trial)	N Engl J Med. 2012;366(7):591–600
Mayo-Smith MF	Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline	JAMA. 1997;278(2):144–151
American Geriatrics Society	2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults	J Am Geriatr Soc. 2023;71(7):2052–2081
Park TW, Saitz R, Ganoczy D, et al	Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics	BMJ. 2015;350:h2698
Lader M	Benzodiazepine harm: how can it be reduced?	Br J Clin Pharmacol. 2014;77(2):295–302